Nubeqa
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved darolutamide (Nubeqa, Bayer) for metastatic castration-sensitive prostate cancer ...
JUNE 3, 2025
New Approval for Darolutamide
The FDA approved an additional indication of darolutamide (Nubeqa, Bayer) in combination with docetaxel for the ...
AUGUST 18, 2022
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
FDA Approves Nubeqa to Treat Prostate Cancer
Bayer's Nubeqa was approved for the treatment of patients with nonmetastatic castration-resistant prostate ...
AUGUST 5, 2019
Load more